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Summary
 
p300 and cAMP response element–binding protein (CREB)–binding protein (CBP) are mem-
bers of a family of coactivators involved in the regulation of transcription and chromatin. We
show that transcription factors of the nuclear factor of activated T cells (NFAT) family bind
p300/CBP and recruit histone acetyltransferase activity from T cell nuclear extracts. The NH
 
2
 
-
terminal transactivation domain of NFAT1 and the phospho-CREB- and E1A-binding sites of
p300/CBP are involved in the interaction. The viral oncoprotein E1A inhibits NFAT-depen-
dent transactivation in a p300-dependent manner. Recruitment of the coactivators p300/CBP
by the transactivation domains of NFAT proteins is likely to play a critical role in NFAT-depen-
dent gene expression during the immune response.
Key words: transcriptional regulation • histone acetyltransferases • T cells • nuclear factor of 
activated T cells • cytokine gene expression
 
H
 
istone acetyltransferases (HATs)
 
1
 
 and histone deacety-
lases have been closely implicated in the mechanism
of transcriptional activation and repression of multiple
genes (for a review, see references 1 and 2). Acetylation of
the NH
 
2
 
-terminal regions of histones is considered to be
crucial for the accessibility of transcription factors to nu-
cleosomal templates. All core histones can be variably
acetylated by a number of proteins designated HAT (1, 3),
which include p300/cAMP response element–binding pro-
tein (CREB)-binding protein (CBP) (4, 5), the p300/
CBP-associated factor P/CAF (6), and the nuclear receptor
coactivator ACTR (7). A diverse and increasing number of
transcription factors and some elements of the basal tran-
scription machinery are able to form stable physical com-
plexes with and respond to the coactivating properties of
p300/CBP (for a review, see references 8 and 9). However,
the precise mechanisms by which transcriptional activators
stimulate the transcriptional machinery through p300/CBP
remain unclear.
p300/CBP coactivators serve also as multifunctional
adaptors that coordinate cell cycle progression with tran-
scriptional regulation (10). These coactivators are recruited
in signaling pathways dependent on p53, a tumor suppres-
sor and a common target for genetic alteration in human
cancers (11). Interestingly, there is accumulating evidence
for the role of CBP and p300 in tumorigenesis (9). Specifi-
cally, certain cases of acute myeloid leukemia have been
linked to recurrent chromosomal translocations that result
in in frame fusions of CBP or p300 to the monocytic leu-
kemia zinc finger protein (12) and myeloid/lymphoid leu-
kemia (13, 14) gene products. Moreover, the viral onco-
protein E1A inhibits host gene transcription, by itself
binding and presumably using the HAT activities of p300/
CBP (9).
The nuclear factor of activated T cells (NFAT) regulates
the inducible transcription of cytokine genes and other
genes critical for the immune response (for a review, see
reference 15), thereby indirectly regulating immune cell
proliferation. The most NH
 
2
 
-terminal region (
 
z
 
100 amino
acids [aa]) of NFAT proteins contains a strong acidic trans-
activation domain, whose function in resting cells is par-
tially masked by the adjacent regulatory domain (16). We
show here that the NH
 
2
 
-terminal transactivation domains
of NFAT proteins are capable of recruiting HATs. Immu-
noprecipitates of NFAT1 from T cell nuclear extracts con-
tain an associated HAT activity that is accounted for at least
partially by p300/CBP. NFAT-dependent transactivation is
inhibited by the viral oncoprotein E1A in a p300-depen-
dent manner. The p300/CBP proteins, acting as chroma-
tin-remodeling factors and/or interacting with the basal
 
1
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transcription machinery, may play an important role in the
NFAT-dependent expression of inducible genes.
 
Materials and Methods
 
Antibodies.
 
Antihemagglutinin (anti-HA; 12CA5 murine mAb
against the influenza HA peptide; Boehringer Mannheim Bio-
chemicals, Indianapolis, IN) was used to immunoprecipitate HA-
tagged p300. Rabbit polyclonal antibodies against an NH
 
2
 
-termi-
nal peptide (67.1), the DNA-binding domain (DBD), and a
COOH-terminal peptide (anti–NFAT1-C) of NFAT1 were used
as described (17, 18). Tat antibody, used as a negative control for
immunoprecipitation, was provided by Dr. B. Cullen (National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, MD [19]).
 
Plasmids.
 
pLGP3-mNFAT1
 
D
 
Reg (
 
D
 
146–398) was made by
subcloning a SacI-HindIII fragment from pBST
 
D
 
SX into the
expression plasmid pLGP3, between SacI and HindIII in the
multicloning site. pBST
 
D
 
SX was made by removing a fragment
SfiI-XhoI from pBS-mNFAT1-C and religating blunt ends. 6xHis-
hNFAT1(1–415), was made by subcloning pGEX-2T-NFAT1(1–
415)  into the BamHI/HindIII sites of pQE32 (QIAGEN Inc.,
Chatsworth, CA) that had been filled in with Klenow. The con-
struction of pEFBOS-mNFAT1-C, pLGP3-mNFAT1-C, GAL4-
hNFAT1(1–415), GAL4-
 
D
 
SP2, and GAL4-hNFAT2(1–418) has
been described previously (16, 20). The NFAT luciferase reporter
plasmid (NFAT3x-Luc) containing three copies of the distal
NFAT site of the murine IL-2 promoter (21), was provided by
Dr. D. McKean (Mayo Clinic, Rochester, MN). The GAL4-
luciferase reporter plasmid (GAL4-Luc) (22), the cDNA plasmids
pCMV
 
b
 
-HA-p300, pCMV
 
b
 
-E1A (23), the E1A mutant defec-
tive in binding to p300 (pE1A.15-35 [24]), and plasmids encod-
ing the glutathione 
 
S
 
-transferase (GST)-CBP fusion proteins,
CBP1 (aa 1–117), CBP2 (aa 117–737), CBP3 (aa 737–1626), and
CBP4 (aa 1680–1891) (25), were provided by Dr. M. Montminy
(Joslin Diabetes Center, Boston, MA). pRSV–human growth
hormone (hGH) was used to normalize transfection levels.
 
Transient Transfection.
 
Plasmid DNAs were introduced into
Jurkat human T cells by electroporation (0.25 V, 960 
 
m
 
F) using a
gene pulser (Bio-Rad Laboratories, Hercules, CA) and 0.4-cm
gap cuvettes (26). Transfection of 293T cells (human embryonic
kidney fibroblasts), originally referred to as 293tsA1609neo (27),
was performed using the calcium phosphate coprecipitation tech-
nique. For each lane of the immunoprecipitation experiments, five
10-cm dishes with 0.5 
 
3
 
 10
 
6
 
 cells each were transfected with 4 
 
m
 
g
plasmid DNA. 36 h after transfection, cells were stimulated for 25
min at 37
 
8
 
C with 1 
 
m
 
M ionomycin and 10 nM PMA or left un-
treated, before lysis and immunoprecipitation. Transfection experi-
ments for transactivation studies were performed in Jurkat cells.
 
Cell Extracts and Immunoprecipitation.
 
Whole-cell extracts were
prepared from transfected 293T cells using buffer A (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton, 10%
glycerol, 20 mM sodium pyrophosphate, 1 mM dithiothreitol,
0.4 mM PMSF, 100 
 
m
 
g/ml aprotinin, 25 
 
m
 
M leupeptin). Cell ly-
sates (5 
 
3
 
 10
 
6
 
 cells/ml) were incubated for 10 min at 4
 
8
 
C and
cleared by centrifugation at 2,500 
 
g
 
 for 10 min at 4
 
8
 
C. High salt
nuclear extracts from the murine T cell line Cl.7W2 (28) were
prepared as described previously (29). Cell extracts were pre-
cleared with protein A and B–Sepharose (Pharmacia Biotech, Pis-
cataway, NJ) for 1 h at 4
 
8
 
C and immunoprecipitated for 3 h at
4
 
8
 
C. Samples were analyzed by Western blotting (ECL kit; New
England Nuclear, Boston, MA) or used for HAT assays.
 
HAT Assay.
 
HAT assays were performed using a modifica-
tion of the assay described previously (30). Nuclear extracts from
Cl.7W2 cells were precleared and immunoprecipitated as de-
scribed above. Beads were washed in buffer B (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 0.4 mM
PMSF, 100 
 
m
 
g/ml aprotinin, 25 
 
m
 
M leupeptin). The HAT assay
was performed in 100 
 
m
 
l buffer B containing 8 
 
m
 
g crude histones
(type IIA; Sigma Chemical Co., St. Louis, MO) and 600 nM
[
 
3
 
H]acetyl-CoA (2.5 Ci/mmol; New England Nuclear). After in-
cubation at 30
 
8
 
C for 1 h, the reaction mixture was spotted onto
P81 phosphocellulose filter paper (Whatman Inc., Clifton, NJ)
and washed with 0.2 M sodium carbonate buffer (pH 9.2).
[
 
3
 
H]Acetyl incorporation into histones was determined by liquid
scintillation counting of dried filters.
 
In Vitro Binding Analysis with GST Fusion Proteins.
 
GST fusion
proteins containing CBP regions 1–4 were expressed in and puri-
fied from 
 
Escherichia coli
 
 as reported previously (25). 6xHis-
hNFAT1(1–415) (0.5 
 
m
 
g), expressed and purified using Ni-
NTA–agarose beads (QIAGEN Inc.), was incubated for 2 h at
4
 
8
 
C with 5–10 
 
m
 
g of CBP-GST fusion proteins immobilized on
glutathione-Sepharose beads. The beads were washed five times
with buffer B and once with the same buffer containing no deter-
gent. Bound NFAT1(1–415) was analyzed by Western blotting
with anti-67.1.
 
Transactivation Experiments.
 
Jurkat cells (12 
 
3
 
 10
 
6
 
) were trans-
fected with 2–5 
 
m
 
g of reporter plasmid DNA, 0.5 
 
m
 
g of pSRV-
hGH plasmid, and 2–5 
 
m
 
g of different NFAT plasmid DNAs. 24 h
after transfection, cells were stimulated overnight with 1 
 
m
 
M ion-
omycin and 10 nM PMA. Cell extracts were assayed for luciferase
activity (Luciferase Assay System; Promega Corp., Madison, WI)
as described previously (26). Transfection efficiencies were deter-
mined by measuring the hGH concentration in the culture media
with a radioimmunometric assay kit (Nichols Institute, San Juan
Capistrano, CA).
 
Results and Discussion
 
NFAT Associates with HATs in T Cell Nuclear Extracts.
 
Cl.7W2 T cells were stimulated with ionomycin and phorbol
esters to localize all endogenous NFAT proteins to the nucleus
and activate their transcriptional activity. Nuclear extracts
were prepared from the activated cells, and NFAT1 was
immunoprecipitated using several antibodies. After extensive
washes, the immune complexes were tested for HAT activity.
As shown in Fig. 1, antibodies directed against the DBD and
COOH-terminal regions of NFAT1 immunoprecipitated
significant levels of HAT activity from stimulated T cell
nuclear extracts compared with the background levels im-
munoprecipitated with an irrelevant antibody. In contrast,
an antibody against an NH
 
2
 
-terminal epitope of NFAT1 im-
munoprecipitated background levels of HAT activity (data
not shown). These data suggested that the HAT interaction
might involve the NH
 
2
 
-terminal region of NFAT1.
 
NFAT Interacts with p300 in Cells.
 
Since p300/CBP pos-
sess intrinsic HAT activity (4, 5) and also associate with
other HATs (6, 7), we asked whether the HAT activity as-
sociated with NFAT1 was accounted for at least partly by
p300/CBP. HA epitope–tagged p300 and NFAT1 were
coexpressed in 293T cells, and the cells were stimulated
with PMA and ionomycin to localize NFAT1 to the nucleus
and activate it transcriptionally. NFAT1 was then immu- 
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noprecipitated from whole-cell lysates, and the immuno-
precipitates were tested for the presence of coprecipitating
HA-p300. Antibodies against the DBD and COOH-termi-
nal regions of NFAT1 coimmunoprecipitated HA-p300, as
judged by Western blotting of the immunoprecipitations
with anti-HA (Fig. 2 
 
A
 
, lanes 
 
3
 
 and 
 
4
 
). Antibody against
the NH
 
2
 
-terminal region of NFAT1 gave very weak coim-
munoprecipitation of HA-p300 (Fig. 2 
 
A
 
, lane 
 
2
 
), which
was only detected by overexposure (data not shown), again
suggesting that the NH
 
2
 
-terminal region of NFAT1 was
involved in the interaction with HA-p300. All antibodies
immunoprecipitated equivalent amounts of NFAT1 (Fig. 2
 
A
 
, 
 
bottom
 
). The antibody control showed no immunoreac-
tive band corresponding to HA-p300 (Fig. 2 
 
A
 
, lane 
 
1
 
), in-
dicating the specificity of the interaction. Conversely, anti-HA
coimmunoprecipitated a fraction of nuclear NFAT1 as
shown by Western blotting with anti-NFAT1 (Fig. 2 
 
B
 
,
lane 
 
2
 
). The coimmunoprecipitated fraction of NFAT1
migrated with higher apparent molecular weight than the
bulk of the NFAT1 protein (compare lanes 
 
1
 
 and 
 
2
 
), sug-
gesting that some posttranslational modification of NFAT1
(e.g., phosphorylation) might be required for that optimal
interaction with p300. These results are the first demon-
stration of an interaction of NFAT transcription factors
with the coactivators and HATs p300 and CBP.
 
The NH
 
2
 
-terminal Region of NFAT1 Interacts with CBP In
Vitro.
 
To identify the region of NFAT1 and p300/CBP
involved in the NFAT1–p300/CBP interaction, we per-
formed binding experiments using bacterially expressed re-
combinant proteins. GST fusion proteins containing different
regions of CBP were incubated with hexahistidine-tagged
NFAT1(1–415), and the level of NFAT1 binding was as-
sessed by Western analysis. These experiments showed that
NFAT1 interacted directly with regions CBP2 (aa 117–
737) and CBP4 (aa 1680–1891), where CBP2 includes the
phospho-CREB–binding site and CBP4 includes the E1A-
binding site (Fig. 3 
 
A
 
). Equivalent amounts of each GST
fusion protein were used in the binding assay as seen by
Ponceau red staining (data not shown). Binding between
CBP and NFAT was specific because no immunoreactive
band was seen with GST alone or with other portions of
CBP. The interaction seen in these in vitro experiments
was weak, and may reflect either the lack of some post-
translational modification of NFAT1 required for optimal
interaction or the lack of an accessory protein present in
nuclear extracts (see Fig. 2 
 
B
 
). The interaction of p300/
CBP with signal transducer and activator of transcription
Stat1 also involves the participation of two widely sepa-
rated regions of p300/CBP (31), although most of the tran-
scription factors described to date interact only with a sin-
gle region (9).
 
An Intact Regulatory Domain Is Not Required for Interaction
with p300.
 
The NH
 
2
 
-terminal region of NFAT1 com-
prises a strong acidic transactivation domain and an adja-
cent regulatory domain, the NFAT homology region (15).
To test the importance of the regulatory domain, we
Figure 1. NFAT1 associates
with HATs in nuclear extracts.
Cl.7W2 T cells were stimulated
with ionomycin and PMA for 25
min at 378C, and nuclear extracts
were immunoprecipitated (i.p.)
with antibodies against the DBD
(aDBD) or a COOH-terminal
peptide (aCt) of NFAT1. An ir-
relevant antibody was used as a
control. The immune complexes
were tested for HAT activity as
described in Materials and Methods. The results are representative of
three independent experiments. Bars, The mean and range of duplicates
in one such experiment.
Figure 2. Interaction of p300
and NFAT1 in cells. (A) 293T
cells expressing NFAT1 and
HA-p300 were stimulated with
ionomycin and PMA for 25 min
at 378C. Whole-cell extracts
were immunoprecipitated (i.p.)
with antibodies against an NH2-
terminal peptide (aNt), the DBD
(aDBD), and a COOH-terminal
peptide (aCt) of NFAT1. An ir-
relevant antibody was used as a
control. The immune complexes
were analyzed by Western blot-
ting for HA-p300 (top) and
NFAT1 (bottom, blot with aNt).
The expressed HA-p300, de-
tected with anti-HA (aHA), ap-
peared as several bands (lanes 5
and  6), and the bottom band
seemed to be preferentially coim-
munoprecipitated with NFAT1
(lanes 3 and 4). (B) Lysates from 293T cells expressing NFAT1 alone,
HA-p300 alone, or both were immunoprecipitated (i.p.) with anti-HA
(aHA), and immune complexes were analyzed by Western blotting for
HA-p300 (top) and NFAT1 (bottom). Input, 1% of the total amount of cell
extract used for immunoprecipitations. Arrows, The different forms de-
tected by immunoblotting.
Figure 3. Regions of NFAT1
and CBP involved in the inter-
action. (A) In vitro binding ex-
periments were performed using
6xHisNFAT1(1–415) and GST-
CBP fusion proteins immobi-
lized on glutathione-Sepharose
beads. After six washes, the sam-
ples were analyzed by Western
blotting analysis for NFAT1. (B)
293T cells coexpressing HA-p300
and either full-length NFAT1
(NFAT1-FL) or NFAT1DReg
were stimulated with ionomycin
and PMA for 25 min at 378C.
Whole-cell extracts were immu-
noprecipitated with anti-HA
(aHA). Immune complexes were
analyzed by Western blotting
for HA-p300 (top) and NFAT1
(bottom). Input, 1% of the total
amount of cell extract used for
immunoprecipitations.  Arrows,
The different forms detected by
immunoblotting.2034 NFAT-dependent Transactivation Regulated by the Coactivators p300/CBP
cotransfected 293T cells with HA-p300 and either full-
length NFAT1 or NFAT1DReg, which lacks aa 146–398
encoding the bulk of the regulatory domain. Immunopre-
cipitation of stimulated cell lysates with anti-HA followed
by Western analysis revealed that NFAT1DReg was still
capable of interaction with p300 (Fig. 3 B, lane 4); indeed,
the interaction was reproducibly stronger than observed
with the full-length protein (compare lanes 3 and 4). A
control antibody, unable to immunoprecipitate HA-tagged
epitope p300, was also unable to precipitate NFAT1DReg
(data not shown). Taken together with the in vitro binding
experiments using recombinant proteins, these data sug-
gested that an intact regulatory domain was not required
for NFAT1–p300 interaction, and that the NH2-terminal
transactivation domain of NFAT1 constituted at least one
region of interaction with p300.
E1A Inhibits NFAT1- and NFAT2-dependent Transactiva-
tion. The functional consequence of the interaction be-
tween p300 and NFAT was investigated by E1A, a viral
protein that interferes with p300/CBP functions (9). Jurkat
T cells were cotransfected with expression vectors encod-
ing these two proteins and a reporter construct containing
the distal NFAT site of the IL-2 promoter (NFAT3x-Luc).
24 h after transfection, cells were stimulated overnight with
1 mM ionomycin and 10 nM PMA to localize NFAT to
the nucleus and activate NFAT-dependent transcription.
Cells were harvested and lysed, and the luciferase assay was
performed. In five experiments, E1A inhibited significantly
NFAT-dependent transactivation (Fig. 4 A). An E1A mu-
tant lacking the binding site for p300 was impaired in its
ability to inhibit NFAT-dependent transactivation, indicat-
ing that the effect was indeed mediated by interference
with p300. E1A was also able to inhibit transactivation me-
diated by NFAT1DReg (D146–398), the protein lacking
the regulatory domain.
Most NFAT-dependent transactivation requires the in-
teraction of NFAT with activating protein-1 (AP-1), a het-
erodimer of Fos and Jun proteins (for a review, see refer-
ence 15). Fos and Jun both interact with p300, and E1A
can modulate AP-1 activity by competing directly for
p300/CBP (32, 33). To determine whether at least part of
the effect of E1A on NFAT-dependent transactivation was
due to interference with the p300–NFAT rather than the
p300–AP-1 interaction, we used GAL4 fusion proteins
containing the NH2-terminal transactivation domains of
NFAT1 and NFAT2 (16). As seen in Fig. 4 B, E1A also in-
hibited transactivation mediated by GAL4-NFAT1(1–145)
and GAL4-NFAT2(1–418), whereas the p300 binding
site–defective mutant of E1A did not. Similar results were
obtained using GAL4-DSP2 (D145-387) (16), a deleted
version containing the NH2-terminal transactivation do-
main but lacking an intact regulatory domain (Fig. 4 B).
Taken together, these data indicated that E1A inhibits
NFAT-dependent transactivation in a p300-dependent
manner, and that an intact regulatory domain of NFAT1
was not required for effective inhibition.
Physiological Implications of the NFAT and p300/CBP In-
teraction. HATs p300 and CBP play a role in cell tran-
scription regulation as well as cell cycle control (9). Tran-
scription of eukaryotic genes is a multistep process with
many potential levels of control, including the assembly of
sequence-specific DNA-binding proteins on gene-regula-
tory elements, and the recruitment of coactivators that fa-
cilitate the activity of the basal transcription complex (8,
34). By interacting with the basal transcription machinery,
p300/CBP may facilitate the recruitment of the RNA
polymerase as part of the holoenzyme complex to NFAT-
dependent promoters (35, 36). Since acetylation of core
histones has been associated with chromatin assembly and
the regulation of gene expression (1, 2), the recruitment of
HAT activity by NFAT might be an important step for the
regulation of NFAT-dependent gene expression in the
context of chromatin during the immune response. Specific
interactions with coactivators, in conjunction with the dis-
tinct site preferences of NFAT family proteins, may deter-
mine the cell-specific expression of inducible genes.
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Figure 4. E1A inhibits NFAT-dependent transactivation in a p300-depen-
dent manner. (A) The NFAT3x-Luc reporter plasmid and expression
plasmids encoding full-length NFAT1 (NFAT1-FL) or NFAT1DReg
were cotransfected into Jurkat cells along with expression plasmids encod-
ing wild-type E1A (WT) or the E1A mutant defective for p300 binding
(Mut). (B) The GAL4-Luc reporter and expression plasmid encoding
GAL4-NFAT1(1–415), GAL4-NFAT2(1–418), or GAL4-NFAT1DSP2
were cotransfected into Jurkat cells along with expression plasmids encod-
ing wild-type E1A (WT) or the E1A mutant defective in p300 binding
(Mut). After 36 h of transfection, cells were left unstimulated or stimulated
overnight with ionomycin and PMA and assayed for luciferase assay. Re-
sults are representative of several experiments. Transfection efficiencies
were normalized by measuring hGH expression from a cotransfected
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